Hoth Therapeutics Inc (RKTO) Stock Analysis
Verdict: AVOID
A pivot into defense AI cannot mask chronic EPS misses and a cash runway shorter than 12 months — dilution is the primary catalyst here.
Investment score: 22/100
Analysis as of
Is Hoth Therapeutics Inc stock worth reviewing? The TradeMates thesis
Hoth Therapeutics is a distressed microcap. Despite analyst 'Buy' ratings, the fundamental reality is an accelerating cash burn and a total lack of revenue. The move into defense AI is highly suspect for a 6-person biotech firm.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Hoth Therapeutics Inc opportunities and risks
What speaks for RKTO
- Defense AI Pivot Sentiment
What speaks against RKTO
- Immediate Dilution Risk
Peers and competitors
- MIRA
- HYPD
- VERU
- GRCE
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RKTO | n/a | 0.0x | n/a | 0.0% | 0.0% | -30.3% |
| MIRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.5% |
| HYPD | n/a | 12.7x | n/a | 63.7% | -3163.0% | -572.2% |
| VERU | n/a | 0.0x | n/a | 0.0% | 0.0% | -49.8% |
| GRCE | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.5% |
| GRCE | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.5% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.5% |
Frequently asked questions about Hoth Therapeutics Inc (RKTO)
Is RKTO stock a good investment?
The TradeMates model rates Hoth Therapeutics Inc as AVOID with an investment score of 22/100. Hoth Therapeutics is a distressed microcap. Despite analyst 'Buy' ratings, the fundamental reality is an accelerating cash burn and a total lack of revenue. The move into defense AI is highly suspect for a 6-person biotech firm. This is algorithmic model output, not personal investment advice.
Is RKTO stock a buy?
The TradeMates model verdict for RKTO is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.